Hatteras Venture Partners

Portfolio Companies 2026 for Hatteras Venture Partners: investors, rounds, and co-investor patterns from StartupFundraising.com research, updated for 2026.

Hatteras Venture Partners accounts for 21 tracked companies with verified cap-table data, 21 of which disclose round sizes totalling $5.3B. The median disclosed raise is $158M, and the largest is HistoSonics at $2.3B, ahead of Standard Bariatrics ($350M) and Vigil Neuroscience ($350M).

The names that recur most often on these portfolio cap tables are Hatteras Venture Partners (21 companies), Alexandria Venture Investments (3 companies), New Enterprise Associates (3 companies), Lumira Ventures (2 companies), Atlas Venture (2 companies), Northpond Ventures (2 companies). By latest disclosed round, the market skews Series A (6), Series B (4), Series C (3), IPO (2).

Best funded Hatteras Venture Partners companies

  1. HistoSonics — $2.3B (latest: IPO)
  2. Standard Bariatrics — $350M (latest: Series B)
  3. Vigil Neuroscience — $350M (latest: IPO)
  4. CVRx — $340M
  5. Endeavor BioMedicines — $292M (latest: Series A)
  6. Elligo Health Research — $250M (latest: Series E)
  7. Myeloid Therapeutics — $195M (latest: Series A)
  8. Viamet Pharmaceuticals — $178M (latest: Series D)
  9. PhaseBio Pharmaceuticals — $168M (latest: Series D)
  10. Qpex Biopharma — $165M (latest: Series A)
  11. Atsena Therapeutics — $158M (latest: Series C)
  12. Endogenex — $138M (latest: Series C)
  13. StrideBio — $82M (latest: Series B)
  14. AtaCor Medical — $62M (latest: Series C)
  15. Sensorium Therapeutics — $56M (latest: Series A)

Hatteras Venture Partners — related firms and companies (56)

Hatteras Venture Partners alternatives · All research reports